Inclusion of phase III clinical trial costs in health economic evaluations

• मुख्य लेखक: Afschin Gandjour (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: BMC, 2024-10-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Introduction Protocol-driven trial activities contribute to the utility gain demonstrated in the phase III clinical trial of a new drug. If this utility gain cannot be distinguished from the effects of the new drug itself, protocol-driven trial costs cannot be easily dismissed for consisten...